{"id":"azd6234","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Diarrhea"},{"rate":"30-50%","effect":"Nausea"},{"rate":"20-40%","effect":"Vomiting"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Cough"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting these enzymes, AZD6234 disrupts the PI3K/AKT signaling pathway, which is involved in the regulation of cell growth and survival. This can lead to the inhibition of cancer cell proliferation and survival, making it a potential therapeutic agent for various types of cancer.","oneSentence":"AZD6234 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:21.347Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)"},{"name":"Relapsed or refractory follicular lymphoma"}]},"trialDetails":[{"nctId":"NCT07013643","phase":"PHASE1","title":"A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-04","conditions":"Healthy Participants","enrollment":75},{"nctId":"NCT06851858","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-12","conditions":"Endocrinology, Diabetes, Type II, Obesity","enrollment":69},{"nctId":"NCT06132841","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-13","conditions":"Healthy Participants","enrollment":104},{"nctId":"NCT06862791","phase":"PHASE2","title":"A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-02-18","conditions":"Obesity or Overweight","enrollment":377},{"nctId":"NCT07017179","phase":"PHASE2","title":"This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-05-20","conditions":"Obesity/Overweight","enrollment":871},{"nctId":"NCT06151964","phase":"PHASE1, PHASE2","title":"A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-09-29","conditions":"Overweight and Obesity","enrollment":118},{"nctId":"NCT06595238","phase":"PHASE2","title":"A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-10-01","conditions":"Obesity or Overweight","enrollment":262},{"nctId":"NCT06845813","phase":"PHASE1","title":"Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-02-24","conditions":"Renal Impairment","enrollment":24},{"nctId":"NCT07220954","phase":"PHASE1","title":"A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-10","conditions":"Healthy Participants","enrollment":21},{"nctId":"NCT05511025","phase":"PHASE1","title":"Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-09-20","conditions":"Healthy Participants","enrollment":54}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dose 1"],"phase":"phase_2","status":"active","brandName":"AZD6234","genericName":"AZD6234","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD6234 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. Used for Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), Relapsed or refractory follicular lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}